SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
IPO Year: 2018
Exchange: NASDAQ
Website: si-bone.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/27/2026 | $21.00 | Buy | TD Cowen |
| 8/6/2024 | $27.00 → $19.00 | Buy | Needham |
| 3/28/2024 | $25.00 | Overweight | Piper Sandler |
| 10/12/2022 | $20.00 | Buy | Jefferies |
| 4/7/2022 | $34.00 | Overweight | Cantor Fitzgerald |
| 3/1/2022 | $30.00 → $28.00 | Overweight | Morgan Stanley |
| 1/18/2022 | $43.00 → $36.00 | Buy | B of A Securities |
| 12/21/2021 | $35.00 → $30.00 | Buy | Truist Securities |
| 11/9/2021 | $42.00 → $36.00 | Market Outperform | JMP Securities |
| 8/3/2021 | $41.00 → $40.00 | Overweight | Morgan Stanley |
8-K - SI-BONE, Inc. (0001459839) (Filer)
10-Q - SI-BONE, Inc. (0001459839) (Filer)
8-K - SI-BONE, Inc. (0001459839) (Filer)
DEFA14A - SI-BONE, Inc. (0001459839) (Filer)
DEF 14A - SI-BONE, Inc. (0001459839) (Filer)
SCHEDULE 13G/A - SI-BONE, Inc. (0001459839) (Subject)
S-8 - SI-BONE, Inc. (0001459839) (Filer)
S-3ASR - SI-BONE, Inc. (0001459839) (Filer)
10-K - SI-BONE, Inc. (0001459839) (Filer)
8-K - SI-BONE, Inc. (0001459839) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
Fastest customizable press release news feed in the world
SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the second quarter of 2026 after market close on Monday, August 3, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/4chyjb8g/. Live audio of the webcast will be available on the "Investors" section of the company’s website at: www.si-bone.com. The webca
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets disciplineTom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board MemberAppointments build the financial and governance foundation for ViCentra’s next phase, following the recent scale-up of commercial manufacturing UTRECHT, The Netherlands, July 14, 2026 (GLOBE NEWSWIRE) -- ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced the appointment of Ian Wells as Ch
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 16, 2026, at 5:40 a.m. Pacific Time/ 8:40 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/b4rPMsFmx6FA94q8B8jb82. Live audio of the webcast will be available on the "Investors" section of the company's webs
First Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $52.6 million, representing growth of 11.2%U.S. revenue of $49.3 million, representing growth of 10.0%Gross margin of 79.8% Net loss of $4.3 million, representing an improvement of 33.8% Adjusted EBITDA of $2.5 million, representing an improvement of over 440%$144.7 million in cash and equivalents Recent Operational Highlights (any comparisons are to the prior year period) Over 1,650 active U.S. physicians, representing growth of 17% $2.2 million in trailing 12-month average revenue per territory, representing an increase of 11%Expanded international presence with the launch
SANTA CLARA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 BofA Securities Healthcare Conference in Las Vegas, NV. Management will be hosting a fireside chat on Tuesday, May 12, 2026, at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2026/f3F578.cfm. Live audio of the webcast will be available on the "Investors" section of the c
SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the first quarter of 2026 after market close on Monday, May 11, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/vde24u4q. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast
Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announced it has signed a distribution agreement with SI-BONE, focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith+Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens our position in high-frequency, high-impact trauma procedures."We're incredibly excited to partner with SI-BONE," said Scott Gunn, Vice President Trauma, Extremities and Shoulder. "This collaboration reflects a share
Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $56.3 million, representing growth of 15.0%U.S. revenue of $53.5 million, representing growth of 13.9%Gross margin of 79.0%Net loss of $1.6 million, r
SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Management will be hosting a fireside chat on Monday, March 2, 2026, at 7:30 a.m. Pacific Time/ 10:30 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/hkU3gw9TuYE3fDbRaRPY9r. Live audio of the webcast will be available on the "Investors" sect
SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/zfxy6yox. Live audio of the webcast will be available on the "Investors" section of the company's websi
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
TD Cowen initiated coverage of SI-BONE with a rating of Buy and set a new price target of $21.00
Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $19.00 from $27.00 previously
Piper Sandler initiated coverage of SI-BONE with a rating of Overweight and set a new price target of $25.00
Jefferies initiated coverage of SI-BONE with a rating of Buy and set a new price target of $20.00
Cantor Fitzgerald resumed coverage of SI-BONE with a rating of Overweight and set a new price target of $34.00
Morgan Stanley reiterated coverage of SI-BONE with a rating of Overweight and set a new price target of $28.00 from $30.00 previously
B of A Securities reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $36.00 from $43.00 previously
Truist Securities reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $30.00 from $35.00 previously
JMP Securities reiterated coverage of SI-BONE with a rating of Market Outperform and set a new price target of $36.00 from $42.00 previously
Morgan Stanley reiterated coverage of SI-BONE with a rating of Overweight and set a new price target of $40.00 from $41.00 previously
Live Leadership Updates
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets disciplineTom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board MemberAppointments build the financial and governance foundation for ViCentra’s next phase, following the recent scale-up of commercial manufacturing UTRECHT, The Netherlands, July 14, 2026 (GLOBE NEWSWIRE) -- ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced the appointment of Ian Wells as Ch
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with
Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company's board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay's total board membership to seven. "We are pleased to welcome these two transformational business leaders as new independent directors on the Board," said David Brabazon, Chairman of the Mainstay Board of Directors. "Their deep experience will be invaluable to Mainstay as we grow our business and pursue our mission to serve patients with intractable chronic low back pain." "As our business evolves and we continue to focus on commercial growth, broadening the industry expertise on our Board will help
SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company's Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021. The appointment of Mr. Maheshwari completes the recently announced senior leadership transition which includes Laura Francis succeeding Jeff Dunn as Chief Executive Officer, and Tony Recupero becoming President, Commercial Operations. Jeff Dunn will remain with the compa
Laura Francis to Become Chief Executive Officer; Jeff Dunn to Become Executive Chairman; and Tony Recupero to Become President. SANTA CLARA, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE” or the “Company”), a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, today announced its intention to appoint Laura Francis as Chief Executive Officer and to the board of directors. Laura Francis currently serves as SI-BONE’s Chief Financial Officer and Chief Operating Officer. As CEO, Laura Francis will succeed Jeff Dunn, who will remain with the Company as Execut
This live feed shows all institutional transactions in real time.
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)
Live finance-specific insights
SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the second quarter of 2026 after market close on Monday, August 3, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/4chyjb8g/. Live audio of the webcast will be available on the "Investors" section of the company’s website at: www.si-bone.com. The webca
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 16, 2026, at 5:40 a.m. Pacific Time/ 8:40 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/b4rPMsFmx6FA94q8B8jb82. Live audio of the webcast will be available on the "Investors" section of the company's webs
First Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $52.6 million, representing growth of 11.2%U.S. revenue of $49.3 million, representing growth of 10.0%Gross margin of 79.8% Net loss of $4.3 million, representing an improvement of 33.8% Adjusted EBITDA of $2.5 million, representing an improvement of over 440%$144.7 million in cash and equivalents Recent Operational Highlights (any comparisons are to the prior year period) Over 1,650 active U.S. physicians, representing growth of 17% $2.2 million in trailing 12-month average revenue per territory, representing an increase of 11%Expanded international presence with the launch
SANTA CLARA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 BofA Securities Healthcare Conference in Las Vegas, NV. Management will be hosting a fireside chat on Tuesday, May 12, 2026, at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2026/f3F578.cfm. Live audio of the webcast will be available on the "Investors" section of the c
SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the first quarter of 2026 after market close on Monday, May 11, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/vde24u4q. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast
Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $56.3 million, representing growth of 15.0%U.S. revenue of $53.5 million, representing growth of 13.9%Gross margin of 79.0%Net loss of $1.6 million, r
SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Management will be hosting a fireside chat on Monday, March 2, 2026, at 7:30 a.m. Pacific Time/ 10:30 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/hkU3gw9TuYE3fDbRaRPY9r. Live audio of the webcast will be available on the "Investors" sect
SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/zfxy6yox. Live audio of the webcast will be available on the "Investors" section of the company's websi
SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, December 2, 2025, at 9:00 a.m. Pacific Time/ 12:00 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: SIBN Investors. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay
Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.7 million, representing growth of 20.6% U.S. revenue of $46.4 million, representing growth of 21.2%Gross margin of 79.8%, representing an improvement of 75 basis pointsNet loss of $4.6 million, representing an improvement of 30.6% Positive adjusted EBITDA of $2.3 millionPositive cash from operating activities of $2.3 million$145.7 million in cash and equivalents Recent Operational Highlights (any comparisons are to the prior year period) 1,530 activ